Skip to Content

Benlysta Approval History

  • FDA approved: Yes (First approved March 10th, 2011)
  • Brand name: Benlysta
  • Generic name: belimumab
  • Dosage form: Injection
  • Company: Human Genome Sciences, Inc. and GlaxoSmithKline
  • Treatment for: Systemic Lupus Erythematosus

Benlysta (belimumab) is B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus.

Development History and FDA Approval Process for Benlysta

DateArticle
Mar 10, 2011Approval FDA Approves Benlysta to Treat Lupus
Dec  6, 2010GlaxoSmithKline and Human Genome Sciences announce FDA extension of Benlysta PDUFA target date to 10th March 2011
Nov 17, 2010Human Genome Sciences and GlaxoSmithKline Announce Vote of FDA Advisory Committee to Recommend Approval of Benlysta for Systemic Lupus Erythematosus
Aug 19, 2010Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for Benlysta (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus
Jul 13, 2010Human Genome Sciences and Lonza Enter Commercial Manufacturing Agreement for Benlysta, a Potential New Treatment for Systemic Lupus Erythematosus
Jun 10, 2010Human Genome Sciences Announces Submission of Biologics License Application to FDA for Benlysta (belimumab)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide